Skip to main content
75°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptevo Therapeutics Inc
(NQ:
APVO
)
0.4320
-0.0081 (-1.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aptevo Therapeutics Inc
< Previous
1
2
Next >
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...
From
Aptevo Therapeutics
Via
AccessWire
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
April 12, 2022
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo...
From
Aptevo Therapeutics
Via
AccessWire
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
March 29, 2022
Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a...
From
Aptevo Therapeutics
Via
AccessWire
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
March 24, 2022
SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...
From
Aptevo Therapeutics
Via
AccessWire
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
February 09, 2022
APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to Transplant SEATTLE, WA / ACCESSWIRE / February 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or...
From
Aptevo Therapeutics
Via
AccessWire
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
January 21, 2022
Vice Chairman, John E. Niederhuber, M.D., to Assume Chairmanship, Effective April 1, 2022 SEATTLE, WA / ACCESSWIRE / January 21, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company")...
From
Aptevo Therapeutics
Via
AccessWire
Topics
Retirement
Exposures
Pension
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
December 15, 2021
LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the...
From
Aptevo Therapeutics
Via
AccessWire
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
November 23, 2021
SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
November 15, 2021
SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
November 12, 2021
SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
November 11, 2021
Data support Advancement into the Clinic LUND, SWEDEN, and SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") today announce...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
November 11, 2021
Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
October 27, 2021
SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
October 26, 2021
SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
September 28, 2021
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
August 17, 2021
- Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies - Data was...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
August 12, 2021
SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
July 16, 2021
SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
June 29, 2021
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Lead
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
May 27, 2021
Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo")...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
May 26, 2021
- Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving...
From
Aptevo Therapeutics
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
COVID-19
Death
Intellectual Property
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
May 11, 2021
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
April 09, 2021
SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.